Liposomal Grb-2: Preliminary Phase I data

Preliminary data from 6 evaluable patients in the first cohort of a dose-escalation, U.S. Phase I trial showed that twice-weekly 5 mg/m 2 IV BP-100-1.01 for 4 weeks was well tolerated with no treatmen...